These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Not reported 2006-006886-18 Efficacy and Safety of Vivitrol® in Adults Completing Inpatient Treatment for Alcohol Dependence 2011-01-04 due-trials
Reported results 2012-003445-15 A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of ALKS 9072 in Subjects with Acute Exacerbation of Schizophrenia 2014-03-11 due-trials
Reported results 2012-003996-20 A Phase 3, Multicenter, Extension of Study ALK9072-003 to Assess the Long-term Safety and 2015-04-28 due-trials
Reported results 2013-002193-45 A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALK 3831, in Adults with Schizophrenia Treated with Olanzapine 2015-03-09 due-trials
Reported results 2014-000379-14 A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-5 Study) 2016-09-27 due-trials
Reported results 2014-000380-41 A Phase 3 Multicenter Study of the Long-term Safety and Tolerability of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder in Adults who Have an Inadequate Response to Antidepressant ... 2017-11-20 due-trials
Listed as ongoing, but also has a completion date and reported results 2014-000399-25 A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the 2015-12-23 bad-data
Reported results 2014-001211-39 A Phase 2, Efficacy, Safety, and Tolerability Study of ALKS 3831 in Schizophrenia with Alcohol Use Disorder 2017-02-01 due-trials
Listed as ongoing, but also has a completion date and reported results 2015-003373-15 A Phase 3 Study to Determine the Antipsychotic Efficacy and Safety of ALKS 3831 in Adult Subjects with Acute Exacerbation of Schizophrenia 2017-06-07 bad-data
Listed as ongoing, but also has a completion date 2015-003880-13 A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia 2018-06-18 bad-data
Ongoing 2015-005160-41 A Phase 3 Open Label Study to Evaluate the Long-term Safety and Tolerability of ALKS 8700 in Adults with Relapsing Remitting Multiple Sclerosis not-yet-due
Ongoing 2017-000497-11 A Study to Evaluate the Effect of ALKS 3831 Compared to Olanzapine on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness not-yet-due
Ongoing 2017-000918-36 A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subjects with Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder not-yet-due
Ongoing 2017-001294-16 A Phase 3 Study in Subjects with Relapsing Remitting Multiple Sclerosis to Evaluate the Tolerability of ALKS 8700 and Dimethyl Fumarate not-yet-due